1 to 10 of 36 literature results

• Malignant mesothelioma.

  Malignant mesothelioma is an aggressive, treatment-resistant tumour, which is increasing in frequency throughout the world. Although the main risk fac…

  Authors: Bruce W S Robinson, Arthur W Musk, Richard A Lake

  Source: Lancet. 2005 Jul 30-Aug 5

  View Full Text

• A novel SV40 TAg transgenic model of asbestos-induced mesothelioma: malignant transformation is dose dependent.

  Although it has been clear for >40 years that mesothelioma can be caused by asbestos, not all patients with this disease have a history of asbestos ex…

  Authors: Cleo Robinson, Ivonne van Bruggen, Amanda Segal, Melissa Dunham, Amanda Sherwood, Frank Koentgen, Bruce W S Robinson, Richard A Lake

  Source: Cancer research. 2006 Nov 15

  View Full Text

• Combined chemoimmunotherapy of solid tumours: improving vaccines?

  Cytotoxic chemotherapy not only affects the tumour but also targets dividing lymphocytes, the very cells required to develop an immune response. Hence…

  Authors: Anna K Nowak, Richard A Lake, Bruce W S Robinson

  Source: Advanced drug delivery reviews. 2006 Oct 1

  View Full Text

• Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity.

  This review shows how tumor antigen cross-presentation is affected by the major therapeutic modalities including chemotherapy, radiotherapy, and surge…

  Authors: Robbert G van der Most, Andrew Currie, Bruce W S Robinson, Richard A Lake

  Source: Cancer research. 2006 Jan 15

  View Full Text

• Mesothelin-family proteins and diagnosis of mesothelioma.

  BACKGROUND: Mesothelioma is a highly aggressive tumour for which there are no reliable serum tumour markers. Identification of such a marker would be …

  Authors: Bruce W S Robinson, Jenette Creaney, Richard Lake, Anna Nowak, A William Musk, Nick de Klerk, Pernilla Winzell, Karl Erik Hellstrom, Ingegerd Hellstrom

  Source: Lancet. 2003 Nov 15

  View Full Text

• Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.

  Cytotoxic chemotherapy is generally considered immunosuppressive, with neutropenia and lymphopenia being common adverse side effects. In this context,…

  Authors: Anna K Nowak, Bruce W S Robinson, Richard A Lake

  Source: Cancer research. 2003 Aug 1

  View Full Text

• Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy.

  Resection alone is rarely curative for advanced tumors, but the outcome generally improves with adjuvant therapy. We have previously shown that a comb…

  Authors: Steve Broomfield, Andrew Currie, Robbert G van der Most, Matthew Brown, Ivonne van Bruggen, Bruce W S Robinson, Richard A Lake

  Source: Cancer research. 2005 Sep 1

  View Full Text

• Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma.

  BACKGROUND: The diagnosis of malignant mesothelioma is frequently difficult, the most common differential diagnosis being reactive pleural conditions …

  Authors: Jenette Creaney, Deborah Yeoman, Leanne K Naumoff, Michelle Hof, Amanda Segal, Arthur William Musk, Nicholas De Klerk, Nora Horick, Steven J Skates, Bruce W S Robinson

  Source: Thorax. 2007 Jul

  View Full Text

• Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy.

  Most cytotoxic drugs have gross effects on the immune system, such as neutropenia and lymphopenia. However, their effects on tumor-specific immune res…

  Authors: Anna K Nowak, Bruce W S Robinson, Richard A Lake

  Source: Cancer research. 2002 Apr 15

  View Full Text

• Deliberately provoking local inflammation drives tumors to become their own protective vaccine site.

  Anti-cancer immunotherapies aim to generate resolution of all existing tumors, including inaccessible ones, and provide long-term protection against r…

  Authors: Connie Jackaman, Andrew M Lew, Yifan Zhan, Jane E Allan, Biljana Koloska, Peter T Graham, Bruce W S Robinson, Delia J Nelson

  Source: International immunology. 2008 Nov

  View Full Text